View ValuationL&C BIOLTD 将来の成長Future 基準チェック /66L&C BIOLTD利益と収益がそれぞれ年間148.5%と39.2%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に22.7% 148.9%なると予測されています。主要情報148.5%収益成長率148.91%EPS成長率Biotechs 収益成長20.8%収益成長率39.2%将来の株主資本利益率22.75%アナリストカバレッジLow最終更新日14 Jul 2026今後の成長に関する最新情報Price Target Changed • Jul 06Price target increased by 11% to ₩99,000Up from ₩89,000, the current price target is an average from 3 analysts. New target price is 27% above last closing price of ₩78,200. Stock is up 155% over the past year. The company is forecast to post earnings per share of ₩988 next year compared to a net loss per share of ₩5,816 last year.すべての更新を表示Recent updatesPrice Target Changed • Jul 06Price target increased by 11% to ₩99,000Up from ₩89,000, the current price target is an average from 3 analysts. New target price is 27% above last closing price of ₩78,200. Stock is up 155% over the past year. The company is forecast to post earnings per share of ₩988 next year compared to a net loss per share of ₩5,816 last year.New Risk • Jun 08New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 16% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. This is currently the only risk that has been identified for the company.Reported Earnings • Mar 27Full year 2025 earnings: EPS and revenues miss analyst expectationsFull year 2025 results: ₩5,815 loss per share (down from ₩6,394 profit in FY 2024). Revenue: ₩85.5b (up 19% from FY 2024). Net loss: ₩138.3b (down 195% from profit in FY 2024). Revenue missed analyst estimates by 3.5%. Earnings per share (EPS) also missed analyst estimates by 113%. Revenue is forecast to grow 49% p.a. on average during the next 2 years, compared to a 21% growth forecast for the Biotechs industry in South Korea. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has increased by 42% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Mar 12L&C BIO Co.,LTD, Annual General Meeting, Mar 31, 2026L&C BIO Co.,LTD, Annual General Meeting, Mar 31, 2026, at 10:00 Tokyo Standard Time. Location: conference room, 8, dunchon-daero 457beon-gil, jungwon-gu, gyeonggi-do, seongnam South KoreaValuation Update With 7 Day Price Move • Feb 19Investor sentiment improves as stock rises 27%After last week's 27% share price gain to ₩118,300, the stock trades at a trailing P/E ratio of 37.3x. Average trailing P/E is 24x in the Biotechs industry in South Korea. Total returns to shareholders of 434% over the past three years.分析記事 • Jan 30L&C BIO Co.,LTD's (KOSDAQ:290650) P/S Is Still On The Mark Following 51% Share Price BounceL&C BIO Co.,LTD ( KOSDAQ:290650 ) shares have continued their recent momentum with a 51% gain in the last month alone...Valuation Update With 7 Day Price Move • Jan 26Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₩64,900, the stock trades at a trailing P/E ratio of 20.5x. Average forward P/E is 18x in the Biotechs industry in South Korea. Total returns to shareholders of 201% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩30,982 per share.お知らせ • Dec 24L&C BIO Co.,LTD has filed a Follow-on Equity Offering in the amount of KRW 14.999981 billion.L&C BIO Co.,LTD has filed a Follow-on Equity Offering in the amount of KRW 14.999981 billion. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 223,214 Price\Range: KRW 67200Upcoming Dividend • Dec 22Upcoming dividend of ₩50.00 per shareEligible shareholders must have bought the stock before 29 December 2025. Payment date: 15 April 2026. Payout ratio is a comfortable 1.5% but the company is not cash flow positive. Trailing yield: 0.1%. Lower than top quartile of South Korean dividend payers (3.6%). Lower than average of industry peers (0.6%).Valuation Update With 7 Day Price Move • Dec 01Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₩61,500, the stock trades at a trailing P/E ratio of 19.2x. Average forward P/E is 16x in the Biotechs industry in South Korea. Total returns to shareholders of 152% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩31,355 per share.分析記事 • Nov 29L&C BIO Co.,LTD's (KOSDAQ:290650) Price In Tune With RevenuesWith a price-to-sales (or "P/S") ratio of 17.9x L&C BIO Co.,LTD ( KOSDAQ:290650 ) may be sending bearish signals at the...Declared Dividend • Nov 08Dividend of ₩50.00 announcedDividend of ₩50.00 is the same as last year. Ex-date: 29th December 2025 Payment date: 15th April 2026 Dividend yield will be 0.1%, which is lower than the industry average of 0.5%.お知らせ • Nov 07L&C BIO Co.,LTD announces Annual dividend, payable on April 15, 2026L&C BIO Co.,LTD announced Annual dividend of KRW 50.0000 per share payable on April 15, 2026, ex-date on December 29, 2025 and record date on December 31, 2025.Valuation Update With 7 Day Price Move • Oct 01Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to ₩50,800, the stock trades at a trailing P/E ratio of 9.9x. Average forward P/E is 22x in the Biotechs industry in South Korea. Total returns to shareholders of 123% over the past three years.New Risk • Sep 05New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). High level of non-cash earnings (47% accrual ratio).Valuation Update With 7 Day Price Move • Sep 05Investor sentiment improves as stock rises 36%After last week's 36% share price gain to ₩42,150, the stock trades at a trailing P/E ratio of 8.2x. Average forward P/E is 22x in the Biotechs industry in South Korea. Total returns to shareholders of 74% over the past three years.Valuation Update With 7 Day Price Move • Jul 25Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₩34,500, the stock trades at a trailing P/E ratio of 6x. Average trailing P/E is 24x in the Biotechs industry in South Korea. Total returns to shareholders of 16% over the past three years.Valuation Update With 7 Day Price Move • Jul 08Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₩32,000, the stock trades at a trailing P/E ratio of 5.6x. Average trailing P/E is 24x in the Biotechs industry in South Korea. Total returns to shareholders of 3.2% over the past three years.お知らせ • Jun 23L&C BIO Co.,LTD (KOSDAQ:A290650) announces an Equity Buyback for 342,465 shares, for KRW 10,000 million.L&C BIO Co., Ltd (KOSE:A290650) announces a share repurchase program. Under the program, the company will repurchase up to 342,465 shares for KRW 10,000 million. The purpose of the program is to stabilize stock price and enhance shareholder value The share repurchase program is valid until September 23, 2025. As of June 22, 2025, the company had no shares in treasury within scope available for dividend and had no shares in treasury through other repurchase.Valuation Update With 7 Day Price Move • Jun 16Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₩30,400, the stock trades at a trailing P/E ratio of 5.3x. Average trailing P/E is 25x in the Biotechs industry in South Korea. Total loss to shareholders of 8.4% over the past three years.New Risk • May 27New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (55% accrual ratio). Minor Risk Share price has been volatile over the past 3 months (9.4% average weekly change).Valuation Update With 7 Day Price Move • May 21Investor sentiment improves as stock rises 27%After last week's 27% share price gain to ₩29,150, the stock trades at a trailing P/E ratio of 4.7x. Average trailing P/E is 28x in the Biotechs industry in South Korea. Total loss to shareholders of 26% over the past three years.分析記事 • Apr 01L&C BIOLTD's (KOSDAQ:290650) Performance Raises Some QuestionsWe didn't see L&C BIO Co.,LTD's ( KOSDAQ:290650 ) stock surge when it reported robust earnings recently. We decided to...お知らせ • Mar 13L&C BIO Co.,LTD, Annual General Meeting, Mar 31, 2025L&C BIO Co.,LTD, Annual General Meeting, Mar 31, 2025, at 10:00 Tokyo Standard Time. Location: conference room, 8, dunchon-daero 457beon-gil, jungwon-gu, gyeonggi-do, seongnam South Koreaお知らせ • Jan 22L&C Bio Secures NMPA Approval for 'Megaderm Plus' in ChinaL&C Bio has achieved a significant milestone in its global market strategy by becoming the first company worldwide to secure approval from China's National Medical Products Administration (NMPA) for its acellular dermal matrix, "MegaDerm Plus." This approval positions the company to potentially dominate China's regenerative medicine market for human tissue, with full-scale sales expected to commence in the first half of 2025. China has recently faced a shortage of human tissue products due to incidents involving illegal donor acquisitions, leading to unprecedented shutdowns of major local companies. In this challenging environment, "MegaDerm Plus," now officially approved by the Chinese government, has emerged as a pivotal product that could effectively address this shortage. Interest in "MegaDerm Plus" has already surged among China's leading medical device companies, hospitals, and medical professionals, raising strong prospects for consecutive sales agreements. This positions L&C Bio not only for market entry but also for establishing a decisive foothold in China's regenerative medicine market for human tissue.Upcoming Dividend • Dec 20Upcoming dividend of ₩50.00 per shareEligible shareholders must have bought the stock before 27 December 2024. Payment date: 14 April 2025. The company is not currently making a profit and is not cash flow positive. Trailing yield: 0.5%. Lower than top quartile of South Korean dividend payers (3.9%). In line with average of industry peers (0.5%).分析記事 • Dec 14There's No Escaping L&C BIO Co.,LTD's (KOSDAQ:290650) Muted Revenues Despite A 30% Share Price RiseL&C BIO Co.,LTD ( KOSDAQ:290650 ) shareholders would be excited to see that the share price has had a great month...分析記事 • Nov 12Is L&C BIOLTD (KOSDAQ:290650) A Risky Investment?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...分析記事 • Aug 06Here's Why L&C BIOLTD (KOSDAQ:290650) Has A Meaningful Debt BurdenDavid Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Valuation Update With 7 Day Price Move • Aug 05Investor sentiment deteriorates as stock falls 20%After last week's 20% share price decline to ₩16,700, the stock trades at a trailing P/E ratio of 7.7x. Average trailing P/E is 23x in the Biotechs industry in South Korea. Total loss to shareholders of 52% over the past three years.分析記事 • Jul 05What L&C BIO Co.,LTD's (KOSDAQ:290650) 27% Share Price Gain Is Not Telling YouL&C BIO Co.,LTD ( KOSDAQ:290650 ) shareholders would be excited to see that the share price has had a great month...分析記事 • Mar 27L&C Bio's (KOSDAQ:290650) Performance Raises Some QuestionsEven though L&C Bio Co., Ltd ( KOSDAQ:290650 ) posted strong earnings recently, the stock hasn't reacted in a large...Upcoming Dividend • Dec 20Upcoming dividend of ₩100.00 per share at 0.2% yieldEligible shareholders must have bought the stock before 27 December 2023. Payment date: 15 April 2024. Payout ratio is a comfortable 2.1% but the company is not cash flow positive. Trailing yield: 0.2%. Lower than top quartile of South Korean dividend payers (3.5%). Lower than average of industry peers (0.7%).Reported Earnings • Nov 19Third quarter 2023 earnings released: EPS: ₩2,176 (vs ₩14.00 in 3Q 2022)Third quarter 2023 results: EPS: ₩2,176 (up from ₩14.00 in 3Q 2022). Revenue: ₩20.6b (up 61% from 3Q 2022). Net income: ₩49.8b (up ₩49.5b from 3Q 2022). Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 7.9% growth forecast for the Biotechs industry in South Korea. Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings.Valuation Update With 7 Day Price Move • Mar 09Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₩26,300, the stock trades at a trailing P/E ratio of 53.8x. Average trailing P/E is 24x in the Biotechs industry in South Korea. Total returns to shareholders of 72% over the past three years.Upcoming Dividend • Dec 21Upcoming dividend of ₩50.00 per shareEligible shareholders must have bought the stock before 28 December 2022. Payment date: 13 April 2023. Payout ratio is a comfortable 10% but the company is not cash flow positive. Trailing yield: 0.2%. Lower than top quartile of South Korean dividend payers (3.3%). Lower than average of industry peers (0.7%).Valuation Update With 7 Day Price Move • Nov 01Investor sentiment improved over the past weekAfter last week's 15% share price gain to ₩25,100, the stock trades at a trailing P/E ratio of 45.4x. Average trailing P/E is 19x in the Biotechs industry in South Korea. Total returns to shareholders of 211% over the past three years.Valuation Update With 7 Day Price Move • Oct 11Investor sentiment deteriorated over the past weekAfter last week's 25% share price decline to ₩17,500, the stock trades at a trailing P/E ratio of 31.7x. Average trailing P/E is 20x in the Biotechs industry in South Korea. Total returns to shareholders of 117% over the past three years.お知らせ • Jul 01L&C Bio Co., Ltd announced that it has received KRW 60 billion in fundingOn June 29, 2022, L&C Bio Co., Ltd closed the transaction.Valuation Update With 7 Day Price Move • May 23Investor sentiment deteriorated over the past weekAfter last week's 17% share price decline to ₩36,150, the stock trades at a forward P/E ratio of 79x. Average forward P/E is 25x in the Biotechs industry in South Korea. Total returns to shareholders of 373% over the past three years.Upcoming Dividend • Dec 22Upcoming dividend of ₩50.00 per shareEligible shareholders must have bought the stock before 29 December 2021. Payment date: 11 April 2022. Payout ratio is a comfortable 10% and the cash payout ratio is 80%. Trailing yield: 0.1%. Lower than top quartile of South Korean dividend payers (2.4%). Lower than average of industry peers (0.8%).Valuation Update With 7 Day Price Move • Dec 08Investor sentiment improved over the past weekAfter last week's 17% share price gain to ₩36,950, the stock trades at a forward P/E ratio of 65x. Average forward P/E is 26x in the Biotechs industry in South Korea. Total returns to shareholders of 490% over the past three years.Reported Earnings • Nov 15Third quarter 2021 earnings released: EPS ₩77.00 (vs ₩86.00 in 3Q 2020)The company reported a mediocre third quarter result with weaker earnings and profit margins, although revenues improved. Third quarter 2021 results: Revenue: ₩11.9b (up 44% from 3Q 2020). Net income: ₩1.76b (down 6.6% from 3Q 2020). Profit margin: 15% (down from 23% in 3Q 2020). Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has increased by 76% per year, which means it is tracking significantly ahead of earnings growth.分析記事 • Apr 20Does L&C Bio (KOSDAQ:290650) Deserve A Spot On Your Watchlist?Like a puppy chasing its tail, some new investors often chase 'the next big thing', even if that means buying 'story...分析記事 • Apr 01L&C Bio's (KOSDAQ:290650) Earnings Are Of Questionable QualityL&C Bio Co., Ltd's ( KOSDAQ:290650 ) robust earnings report didn't manage to move the market for its stock. Our...分析記事 • Mar 02Is L&C Bio (KOSDAQ:290650) A Risky Investment?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Is New 90 Day High Low • Feb 22New 90-day low: ₩30,400The company is down 17% from its price of ₩36,600 on 24 November 2020. The South Korean market is up 18% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 1.0% over the same period.分析記事 • Feb 03Announcing: L&C Bio (KOSDAQ:290650) Stock Increased An Energizing 163% In The Last YearWhile L&C Bio Co., Ltd ( KOSDAQ:290650 ) shareholders are probably generally happy, the stock hasn't had particularly...Is New 90 Day High Low • Jan 18New 90-day low: ₩30,650The company is down 30% from its price of ₩43,950 on 20 October 2020. The South Korean market is up 30% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 19% over the same period.分析記事 • Jan 04What Is The Ownership Structure Like For L&C Bio Co., Ltd (KOSDAQ:290650)?If you want to know who really controls L&C Bio Co., Ltd ( KOSDAQ:290650 ), then you'll have to look at the makeup of...Is New 90 Day High Low • Dec 28New 90-day low: ₩33,050The company is down 28% from its price of ₩45,667 on 29 September 2020. The South Korean market is up 20% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 15% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ₩5,058 per share.Upcoming Dividend • Dec 22Upcoming Dividend of ₩50.00 Per ShareWill be paid on the 10th of April to those who are registered shareholders by the 29th of December. The trailing yield of 0.09% is below the top quartile of South Korean dividend payers (2.6%), and is lower than industry peers (0.3%).分析記事 • Dec 08Should You Be Excited About L&C Bio Co., Ltd's (KOSDAQ:290650) 16% Return On Equity?While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...Is New 90 Day High Low • Dec 08New 90-day low: ₩34,100The company is down 22% from its price of ₩43,500 on 09 September 2020. The South Korean market is up 13% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 9.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ₩4,530 per share.Reported Earnings • Nov 17Third quarter 2020 earnings released: EPS ₩257The company reported a solid third quarter result with improved earnings and revenues, although profit margins were weaker. Third quarter 2020 results: Revenue: ₩8.32b (up 21% from 3Q 2019). Net income: ₩1.88b (up 14% from 3Q 2019). Profit margin: 23% (down from 24% in 3Q 2019). The decrease in margin was driven by higher expenses.Is New 90 Day High Low • Nov 06New 90-day low: ₩38,950The company is down 15% from its price of ₩45,733 on 07 August 2020. The South Korean market is up 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 7.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ₩4,305 per share.Is New 90 Day High Low • Oct 06New 90-day high: ₩155,600The company is up 44% from its price of ₩108,100 on 08 July 2020. The South Korean market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ₩13,045 per share.業績と収益の成長予測KOSDAQ:A290650 - アナリストの将来予測と過去の財務データ ( )KRW Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/2028320,314N/A51,75085,950412/31/2027262,75174,00040,93364,633512/31/2026165,74324,50047,50042,47553/31/202698,100-135,503-4,45319,399N/A12/31/202585,476-138,285-4,47112,565N/A9/30/202579,93180,408-8966,858N/A6/30/202575,916127,545-7,200783N/A3/31/202573,173142,793-14,300-8,570N/A12/31/202472,032145,038-13,911-8,567N/A9/30/202466,991-3,649-42,845-15,715N/A6/30/202469,00950,471-39,492-15,002N/A3/31/202467,66150,154-32,927-8,488N/A12/31/202365,92748,689-37,057-12,133N/A9/30/202367,48753,593-10,164-5,401N/A6/30/202359,7164,114-28,029-6,684N/A3/31/202356,3703,882-43,417-10,237N/A12/31/202252,5724,544-43,594-6,076N/A9/30/202250,39911,092-43,263-5,744N/A6/30/202249,55312,530-20,9223,186N/A3/31/202247,10113,176-2,82510,715N/A12/31/202145,67713,814-48110,907N/A9/30/202141,57911,0211,36913,245N/A6/30/202137,95611,1468639,259N/A3/31/202135,14111,1072,7678,296N/A12/31/202032,97310,8134,3647,419N/A9/30/202031,8687,2135,0407,791N/A6/30/202030,4106,9784,6887,465N/A3/31/202030,3337,2884,0766,519N/A12/31/201929,1527,250N/A6,431N/A9/30/201927,3486,505N/A4,503N/A6/30/201924,9785,860N/A3,539N/A3/31/201922,6245,521N/A3,404N/A12/31/201821,2415,208N/A3,846N/A9/30/201819,6185,186N/A4,303N/A6/30/201819,9665,396N/A5,019N/A3/31/201818,6314,345N/A4,937N/A12/31/201717,9013,753N/A3,818N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: A290650は今後 3 年間で収益性が向上すると予測されており、これは 貯蓄率 ( 3.1% ) よりも高い成長率であると考えられます。収益対市場: A290650今後 3 年間で収益性が向上すると予想されており、これは市場平均を上回る成長と考えられます。高成長収益: A290650今後 3 年以内に収益を上げることが予想されます。収益対市場: A290650の収益 ( 39.2% ) KR市場 ( 16% ) よりも速いペースで成長すると予測されています。高い収益成長: A290650の収益 ( 39.2% ) 20%よりも速いペースで成長すると予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: A290650の 自己資本利益率 は、3年後には高くなると予測されています ( 22.7 %)成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/18 22:26終値2026/07/16 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋L&C BIO Co.,LTD 5 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。6 アナリスト機関Jonghyun ParkDAOL Investment & Securities Co., Ltd.Chae-eun LeeEugene Investment & Securities Co Ltd.Jun ChoiMacquarie Research3 その他のアナリストを表示
Price Target Changed • Jul 06Price target increased by 11% to ₩99,000Up from ₩89,000, the current price target is an average from 3 analysts. New target price is 27% above last closing price of ₩78,200. Stock is up 155% over the past year. The company is forecast to post earnings per share of ₩988 next year compared to a net loss per share of ₩5,816 last year.
Price Target Changed • Jul 06Price target increased by 11% to ₩99,000Up from ₩89,000, the current price target is an average from 3 analysts. New target price is 27% above last closing price of ₩78,200. Stock is up 155% over the past year. The company is forecast to post earnings per share of ₩988 next year compared to a net loss per share of ₩5,816 last year.
New Risk • Jun 08New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 16% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. This is currently the only risk that has been identified for the company.
Reported Earnings • Mar 27Full year 2025 earnings: EPS and revenues miss analyst expectationsFull year 2025 results: ₩5,815 loss per share (down from ₩6,394 profit in FY 2024). Revenue: ₩85.5b (up 19% from FY 2024). Net loss: ₩138.3b (down 195% from profit in FY 2024). Revenue missed analyst estimates by 3.5%. Earnings per share (EPS) also missed analyst estimates by 113%. Revenue is forecast to grow 49% p.a. on average during the next 2 years, compared to a 21% growth forecast for the Biotechs industry in South Korea. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has increased by 42% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Mar 12L&C BIO Co.,LTD, Annual General Meeting, Mar 31, 2026L&C BIO Co.,LTD, Annual General Meeting, Mar 31, 2026, at 10:00 Tokyo Standard Time. Location: conference room, 8, dunchon-daero 457beon-gil, jungwon-gu, gyeonggi-do, seongnam South Korea
Valuation Update With 7 Day Price Move • Feb 19Investor sentiment improves as stock rises 27%After last week's 27% share price gain to ₩118,300, the stock trades at a trailing P/E ratio of 37.3x. Average trailing P/E is 24x in the Biotechs industry in South Korea. Total returns to shareholders of 434% over the past three years.
分析記事 • Jan 30L&C BIO Co.,LTD's (KOSDAQ:290650) P/S Is Still On The Mark Following 51% Share Price BounceL&C BIO Co.,LTD ( KOSDAQ:290650 ) shares have continued their recent momentum with a 51% gain in the last month alone...
Valuation Update With 7 Day Price Move • Jan 26Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₩64,900, the stock trades at a trailing P/E ratio of 20.5x. Average forward P/E is 18x in the Biotechs industry in South Korea. Total returns to shareholders of 201% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩30,982 per share.
お知らせ • Dec 24L&C BIO Co.,LTD has filed a Follow-on Equity Offering in the amount of KRW 14.999981 billion.L&C BIO Co.,LTD has filed a Follow-on Equity Offering in the amount of KRW 14.999981 billion. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 223,214 Price\Range: KRW 67200
Upcoming Dividend • Dec 22Upcoming dividend of ₩50.00 per shareEligible shareholders must have bought the stock before 29 December 2025. Payment date: 15 April 2026. Payout ratio is a comfortable 1.5% but the company is not cash flow positive. Trailing yield: 0.1%. Lower than top quartile of South Korean dividend payers (3.6%). Lower than average of industry peers (0.6%).
Valuation Update With 7 Day Price Move • Dec 01Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₩61,500, the stock trades at a trailing P/E ratio of 19.2x. Average forward P/E is 16x in the Biotechs industry in South Korea. Total returns to shareholders of 152% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩31,355 per share.
分析記事 • Nov 29L&C BIO Co.,LTD's (KOSDAQ:290650) Price In Tune With RevenuesWith a price-to-sales (or "P/S") ratio of 17.9x L&C BIO Co.,LTD ( KOSDAQ:290650 ) may be sending bearish signals at the...
Declared Dividend • Nov 08Dividend of ₩50.00 announcedDividend of ₩50.00 is the same as last year. Ex-date: 29th December 2025 Payment date: 15th April 2026 Dividend yield will be 0.1%, which is lower than the industry average of 0.5%.
お知らせ • Nov 07L&C BIO Co.,LTD announces Annual dividend, payable on April 15, 2026L&C BIO Co.,LTD announced Annual dividend of KRW 50.0000 per share payable on April 15, 2026, ex-date on December 29, 2025 and record date on December 31, 2025.
Valuation Update With 7 Day Price Move • Oct 01Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to ₩50,800, the stock trades at a trailing P/E ratio of 9.9x. Average forward P/E is 22x in the Biotechs industry in South Korea. Total returns to shareholders of 123% over the past three years.
New Risk • Sep 05New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). High level of non-cash earnings (47% accrual ratio).
Valuation Update With 7 Day Price Move • Sep 05Investor sentiment improves as stock rises 36%After last week's 36% share price gain to ₩42,150, the stock trades at a trailing P/E ratio of 8.2x. Average forward P/E is 22x in the Biotechs industry in South Korea. Total returns to shareholders of 74% over the past three years.
Valuation Update With 7 Day Price Move • Jul 25Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₩34,500, the stock trades at a trailing P/E ratio of 6x. Average trailing P/E is 24x in the Biotechs industry in South Korea. Total returns to shareholders of 16% over the past three years.
Valuation Update With 7 Day Price Move • Jul 08Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₩32,000, the stock trades at a trailing P/E ratio of 5.6x. Average trailing P/E is 24x in the Biotechs industry in South Korea. Total returns to shareholders of 3.2% over the past three years.
お知らせ • Jun 23L&C BIO Co.,LTD (KOSDAQ:A290650) announces an Equity Buyback for 342,465 shares, for KRW 10,000 million.L&C BIO Co., Ltd (KOSE:A290650) announces a share repurchase program. Under the program, the company will repurchase up to 342,465 shares for KRW 10,000 million. The purpose of the program is to stabilize stock price and enhance shareholder value The share repurchase program is valid until September 23, 2025. As of June 22, 2025, the company had no shares in treasury within scope available for dividend and had no shares in treasury through other repurchase.
Valuation Update With 7 Day Price Move • Jun 16Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₩30,400, the stock trades at a trailing P/E ratio of 5.3x. Average trailing P/E is 25x in the Biotechs industry in South Korea. Total loss to shareholders of 8.4% over the past three years.
New Risk • May 27New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (55% accrual ratio). Minor Risk Share price has been volatile over the past 3 months (9.4% average weekly change).
Valuation Update With 7 Day Price Move • May 21Investor sentiment improves as stock rises 27%After last week's 27% share price gain to ₩29,150, the stock trades at a trailing P/E ratio of 4.7x. Average trailing P/E is 28x in the Biotechs industry in South Korea. Total loss to shareholders of 26% over the past three years.
分析記事 • Apr 01L&C BIOLTD's (KOSDAQ:290650) Performance Raises Some QuestionsWe didn't see L&C BIO Co.,LTD's ( KOSDAQ:290650 ) stock surge when it reported robust earnings recently. We decided to...
お知らせ • Mar 13L&C BIO Co.,LTD, Annual General Meeting, Mar 31, 2025L&C BIO Co.,LTD, Annual General Meeting, Mar 31, 2025, at 10:00 Tokyo Standard Time. Location: conference room, 8, dunchon-daero 457beon-gil, jungwon-gu, gyeonggi-do, seongnam South Korea
お知らせ • Jan 22L&C Bio Secures NMPA Approval for 'Megaderm Plus' in ChinaL&C Bio has achieved a significant milestone in its global market strategy by becoming the first company worldwide to secure approval from China's National Medical Products Administration (NMPA) for its acellular dermal matrix, "MegaDerm Plus." This approval positions the company to potentially dominate China's regenerative medicine market for human tissue, with full-scale sales expected to commence in the first half of 2025. China has recently faced a shortage of human tissue products due to incidents involving illegal donor acquisitions, leading to unprecedented shutdowns of major local companies. In this challenging environment, "MegaDerm Plus," now officially approved by the Chinese government, has emerged as a pivotal product that could effectively address this shortage. Interest in "MegaDerm Plus" has already surged among China's leading medical device companies, hospitals, and medical professionals, raising strong prospects for consecutive sales agreements. This positions L&C Bio not only for market entry but also for establishing a decisive foothold in China's regenerative medicine market for human tissue.
Upcoming Dividend • Dec 20Upcoming dividend of ₩50.00 per shareEligible shareholders must have bought the stock before 27 December 2024. Payment date: 14 April 2025. The company is not currently making a profit and is not cash flow positive. Trailing yield: 0.5%. Lower than top quartile of South Korean dividend payers (3.9%). In line with average of industry peers (0.5%).
分析記事 • Dec 14There's No Escaping L&C BIO Co.,LTD's (KOSDAQ:290650) Muted Revenues Despite A 30% Share Price RiseL&C BIO Co.,LTD ( KOSDAQ:290650 ) shareholders would be excited to see that the share price has had a great month...
分析記事 • Nov 12Is L&C BIOLTD (KOSDAQ:290650) A Risky Investment?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
分析記事 • Aug 06Here's Why L&C BIOLTD (KOSDAQ:290650) Has A Meaningful Debt BurdenDavid Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Valuation Update With 7 Day Price Move • Aug 05Investor sentiment deteriorates as stock falls 20%After last week's 20% share price decline to ₩16,700, the stock trades at a trailing P/E ratio of 7.7x. Average trailing P/E is 23x in the Biotechs industry in South Korea. Total loss to shareholders of 52% over the past three years.
分析記事 • Jul 05What L&C BIO Co.,LTD's (KOSDAQ:290650) 27% Share Price Gain Is Not Telling YouL&C BIO Co.,LTD ( KOSDAQ:290650 ) shareholders would be excited to see that the share price has had a great month...
分析記事 • Mar 27L&C Bio's (KOSDAQ:290650) Performance Raises Some QuestionsEven though L&C Bio Co., Ltd ( KOSDAQ:290650 ) posted strong earnings recently, the stock hasn't reacted in a large...
Upcoming Dividend • Dec 20Upcoming dividend of ₩100.00 per share at 0.2% yieldEligible shareholders must have bought the stock before 27 December 2023. Payment date: 15 April 2024. Payout ratio is a comfortable 2.1% but the company is not cash flow positive. Trailing yield: 0.2%. Lower than top quartile of South Korean dividend payers (3.5%). Lower than average of industry peers (0.7%).
Reported Earnings • Nov 19Third quarter 2023 earnings released: EPS: ₩2,176 (vs ₩14.00 in 3Q 2022)Third quarter 2023 results: EPS: ₩2,176 (up from ₩14.00 in 3Q 2022). Revenue: ₩20.6b (up 61% from 3Q 2022). Net income: ₩49.8b (up ₩49.5b from 3Q 2022). Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 7.9% growth forecast for the Biotechs industry in South Korea. Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings.
Valuation Update With 7 Day Price Move • Mar 09Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₩26,300, the stock trades at a trailing P/E ratio of 53.8x. Average trailing P/E is 24x in the Biotechs industry in South Korea. Total returns to shareholders of 72% over the past three years.
Upcoming Dividend • Dec 21Upcoming dividend of ₩50.00 per shareEligible shareholders must have bought the stock before 28 December 2022. Payment date: 13 April 2023. Payout ratio is a comfortable 10% but the company is not cash flow positive. Trailing yield: 0.2%. Lower than top quartile of South Korean dividend payers (3.3%). Lower than average of industry peers (0.7%).
Valuation Update With 7 Day Price Move • Nov 01Investor sentiment improved over the past weekAfter last week's 15% share price gain to ₩25,100, the stock trades at a trailing P/E ratio of 45.4x. Average trailing P/E is 19x in the Biotechs industry in South Korea. Total returns to shareholders of 211% over the past three years.
Valuation Update With 7 Day Price Move • Oct 11Investor sentiment deteriorated over the past weekAfter last week's 25% share price decline to ₩17,500, the stock trades at a trailing P/E ratio of 31.7x. Average trailing P/E is 20x in the Biotechs industry in South Korea. Total returns to shareholders of 117% over the past three years.
お知らせ • Jul 01L&C Bio Co., Ltd announced that it has received KRW 60 billion in fundingOn June 29, 2022, L&C Bio Co., Ltd closed the transaction.
Valuation Update With 7 Day Price Move • May 23Investor sentiment deteriorated over the past weekAfter last week's 17% share price decline to ₩36,150, the stock trades at a forward P/E ratio of 79x. Average forward P/E is 25x in the Biotechs industry in South Korea. Total returns to shareholders of 373% over the past three years.
Upcoming Dividend • Dec 22Upcoming dividend of ₩50.00 per shareEligible shareholders must have bought the stock before 29 December 2021. Payment date: 11 April 2022. Payout ratio is a comfortable 10% and the cash payout ratio is 80%. Trailing yield: 0.1%. Lower than top quartile of South Korean dividend payers (2.4%). Lower than average of industry peers (0.8%).
Valuation Update With 7 Day Price Move • Dec 08Investor sentiment improved over the past weekAfter last week's 17% share price gain to ₩36,950, the stock trades at a forward P/E ratio of 65x. Average forward P/E is 26x in the Biotechs industry in South Korea. Total returns to shareholders of 490% over the past three years.
Reported Earnings • Nov 15Third quarter 2021 earnings released: EPS ₩77.00 (vs ₩86.00 in 3Q 2020)The company reported a mediocre third quarter result with weaker earnings and profit margins, although revenues improved. Third quarter 2021 results: Revenue: ₩11.9b (up 44% from 3Q 2020). Net income: ₩1.76b (down 6.6% from 3Q 2020). Profit margin: 15% (down from 23% in 3Q 2020). Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has increased by 76% per year, which means it is tracking significantly ahead of earnings growth.
分析記事 • Apr 20Does L&C Bio (KOSDAQ:290650) Deserve A Spot On Your Watchlist?Like a puppy chasing its tail, some new investors often chase 'the next big thing', even if that means buying 'story...
分析記事 • Apr 01L&C Bio's (KOSDAQ:290650) Earnings Are Of Questionable QualityL&C Bio Co., Ltd's ( KOSDAQ:290650 ) robust earnings report didn't manage to move the market for its stock. Our...
分析記事 • Mar 02Is L&C Bio (KOSDAQ:290650) A Risky Investment?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Is New 90 Day High Low • Feb 22New 90-day low: ₩30,400The company is down 17% from its price of ₩36,600 on 24 November 2020. The South Korean market is up 18% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 1.0% over the same period.
分析記事 • Feb 03Announcing: L&C Bio (KOSDAQ:290650) Stock Increased An Energizing 163% In The Last YearWhile L&C Bio Co., Ltd ( KOSDAQ:290650 ) shareholders are probably generally happy, the stock hasn't had particularly...
Is New 90 Day High Low • Jan 18New 90-day low: ₩30,650The company is down 30% from its price of ₩43,950 on 20 October 2020. The South Korean market is up 30% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 19% over the same period.
分析記事 • Jan 04What Is The Ownership Structure Like For L&C Bio Co., Ltd (KOSDAQ:290650)?If you want to know who really controls L&C Bio Co., Ltd ( KOSDAQ:290650 ), then you'll have to look at the makeup of...
Is New 90 Day High Low • Dec 28New 90-day low: ₩33,050The company is down 28% from its price of ₩45,667 on 29 September 2020. The South Korean market is up 20% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 15% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ₩5,058 per share.
Upcoming Dividend • Dec 22Upcoming Dividend of ₩50.00 Per ShareWill be paid on the 10th of April to those who are registered shareholders by the 29th of December. The trailing yield of 0.09% is below the top quartile of South Korean dividend payers (2.6%), and is lower than industry peers (0.3%).
分析記事 • Dec 08Should You Be Excited About L&C Bio Co., Ltd's (KOSDAQ:290650) 16% Return On Equity?While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...
Is New 90 Day High Low • Dec 08New 90-day low: ₩34,100The company is down 22% from its price of ₩43,500 on 09 September 2020. The South Korean market is up 13% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 9.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ₩4,530 per share.
Reported Earnings • Nov 17Third quarter 2020 earnings released: EPS ₩257The company reported a solid third quarter result with improved earnings and revenues, although profit margins were weaker. Third quarter 2020 results: Revenue: ₩8.32b (up 21% from 3Q 2019). Net income: ₩1.88b (up 14% from 3Q 2019). Profit margin: 23% (down from 24% in 3Q 2019). The decrease in margin was driven by higher expenses.
Is New 90 Day High Low • Nov 06New 90-day low: ₩38,950The company is down 15% from its price of ₩45,733 on 07 August 2020. The South Korean market is up 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 7.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ₩4,305 per share.
Is New 90 Day High Low • Oct 06New 90-day high: ₩155,600The company is up 44% from its price of ₩108,100 on 08 July 2020. The South Korean market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ₩13,045 per share.